A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas.

Trial Profile

A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
    • 26 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top